CCRM
Erik Mena is a Senior Development Manager in Viral Vector MSAT at CCRM since September 2022, with extensive experience in biomanufacturing and process development. Previously, Erik held the position of Supervisor of Manufacturing - Upstream at the National Research Council Canada, where responsibilities included the startup of a manufacturing department, implementation of GMP manufacturing processes, and management of manufacturing schedules and documentation. Erik has also served in leadership roles at C3i/CETC, overseeing the BioTherapeutics & Vectors unit and ensuring cGMP compliance. Other notable positions include Development Specialist in Human Immunotherapy and Research Associate, contributing significantly to various projects focused on cell culture, molecular diagnostics, and bioprocess optimization. Erik holds a Master of Science in Molecular Biology from Université de Montréal and a Bachelor's degree in Experimental Biology from Universidad Autónoma Metropolitana, complemented by further specialization in Genome Sciences.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.